Cosciens Biopharma(TSX) CSCI

Market CapCA$9.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)-100%
5 Year-96%
1 Year-8%
1 Month+30%
CA$9.89
+7.73%
+0.71Today
Cosciens Biopharma last closing stock price
MetricPriceDate
Last closeCAD 9.892026-10-08
Cosciens Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.03%CAD 8.752026-10-01
1 month+29.96%CAD 7.612026-09-08
3 month+22.1%CAD 8.102026-07-10
Year to date+16.08%CAD 8.522025-12-31
1 year-8.17%CAD 10.772025-10-08
3 year-70.57%CAD 33.602023-10-06
5 year-95.72%CAD 231.002021-10-08
Since inception-100%CAD 420,810.131995-12-19

Cosciens Biopharma Financials at a Glance

Market Cap

CA$9.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.18M

Net Income (TTM)

-$4.74M

EPS (TTM)

-CA$6.20

P/E Ratio

-1.48

Dividend

CA$0.00

Beta (Volatility)

0.78 (Low)

Price

CA$9.89

Volume

709

Open

CA$9.28

Previous Close

CA$9.89

Daily Range

CA$9.28 - CA$9.89

52-Week Range

CA$3.30 - CA$14.80

Estimated Earnings Date

Nov 10, 2026

CSCI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosciens Biopharma

Aeterna Zentaris Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutic drugs and diagnostic tests. Established in 1990 and based in Summerville, South Carolina, the company is known for its flagship product, Macrilen, which is used for diagnosing growth hormone deficiency.

Products and Services
  • Macrilen (macimorelin) for growth hormone deficiency diagnosis
  • COVID-19 vaccine development in partnership with the University Wuerzburg
  • Research on treatments for neuromyelitis optica spectrum disorder and Parkinson's disease
Growth Outlook
  • Strategic partnerships enhance research and development capabilities
  • Potential expansion into oncology applications for Macrilen
  • Focus on innovative therapies positions the company for future growth
Financial Highlights
  • Q2 2024 revenue of $2.34 million, a significant increase from Q1
  • Cash and cash equivalents of $27.8 million as of June 30, 2024
  • Current ratio of 4.33 indicates strong liquidity position
Aeterna Zentaris Inc. operates in the biotechnology sector, leveraging its expertise to address unmet medical needs. The company’s flagship product, Macrilen, is a key asset, with ongoing research exploring its potential in oncology. Recent financial performance shows a notable increase in revenue, reflecting the company's ability to capitalize on its innovative product offerings. The strong liquidity position, indicated by a current ratio of 4.33, provides a solid foundation for future investments and operational stability. Strategic partnerships further enhance the company's growth prospects, positioning it well within the competitive biopharmaceutical landscape.
AI Generated • Oct 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Peter Harry Puccetti, CFA

Website

www.cosciensbio.com

Headquarters

Toronto, ON M5H 4E3, CA

CSCI Financials

Key Financial Metrics (TTM)

Gross Margin

45.30%

Operating Margin

-58.56%

Net Income Margin

-57.93%

Return on Equity

-48.52%

Return on Capital

-177.65%

Return on Assets

-25.17%

Earnings Yield

-67.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$9.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

996.40K

Volume

709

Avg. Volume

872.672

Financials (TTM)

Gross Profit

$3.70M

Operating Income

-$4.79M

EBITDA

-$3.55M

Operating Cash Flow

-$3.69M

Capital Expenditure

-$46.87K

Free Cash Flow

-$3.74M

Cash & ST Invst.

$5.27M

Total Debt

$1.95M

Cosciens Biopharma Performance Analysis

Cosciens Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 7,342,45411.3%
20232023-12-31USD 9,640,81431.3%
20242024-12-31USD 13,133,82236.2%
20252025-12-31USD 10,476,870-20.2%
Cosciens Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-47.4%
Q42025-12-3122.5%
Q12026-03-313.6%
Q22026-06-3064.9%
Cosciens Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -73.12167.0%
20232023-12-31USD -30.56-58.2%
20242024-12-31USD -24.37-20.2%
20252025-12-31USD -13.72-43.7%
Cosciens Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-97.7%
Q42025-12-31-23.5%
Q12026-03-3177.1%
Q22026-06-3086.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.06M

+10.0%

Gross Profit

$1.69M

+71.6%

Gross Margin

55.27%

N/A

Market Cap

CA$9.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$326.68K

N/A

Employees

28

N/A

Net Income

-$196.79K

+92.8%

EBITDA

$739.41K

+135.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.27M

-43.5%

Total Debt

$1.95M

-13.5%

Accounts Receivable

$2.37M

-14.9%

Inventory

$958.44K

-47.4%

Long Term Debt

$1.77M

-13.8%

Short Term Debt

$186.70K

-10.7%

Return on Assets

-25.17%

N/A

Return on Invested Capital

-28.87%

N/A

Free Cash Flow

$563.50K

+112.5%

Operating Cash Flow

$571.27K

+112.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMV.TOIMV Inc.
CA$1.12+0.00%
THNK.VThink Research Corporation
CA$0.32+1.61%
IGX.TOIntelGenx Technologies Corp.
CA$0.24+17.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$107.08-5.34%
NVDANvidia
$230.48-2.94%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
BITOProShares Trust - ProShares Bitcoin ETF
$10.93-1.88%

Questions About CSCI

What is the current price of Cosciens Biopharma?

Cosciens Biopharma is trading at CA$9.89 per share.

What is the 52-week range for Cosciens Biopharma?

Over the past 52 weeks, Cosciens Biopharma has traded between CA$3.30 and CA$14.80.

How much debt does Cosciens Biopharma have?

As of the most recent reporting period, Cosciens Biopharma reported total debt of $2.78M.

How much cash does Cosciens Biopharma have on hand?

Cosciens Biopharma reported $7.49M in cash and cash equivalents in its most recent financial results.

What is Cosciens Biopharma’s dividend yield?

Cosciens Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services